Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats

被引:8
作者
Malin, David [1 ]
Henceroth, Mallori [1 ]
Rao, Gadam Srinivas [1 ]
Campbell, Joseph [1 ]
Ma, Jian-Nong [2 ]
Tsai, Ping-Hsun [1 ]
Kishbaugh, Jordan C. [1 ]
Burstein, Ethan S. [2 ]
机构
[1] Univ Houston Clear Lake, Houston, TX 77058 USA
[2] ACADIA Pharmaceut Inc, San Diego, CA USA
关键词
Nicotine withdrawal; Nicotine dependence; 5-HT(2A)receptor; Pimavanserin; Volinanserin; SEROTONIN (5-HT)(2A); LOCOMOTOR-ACTIVITY; DISEASE PSYCHOSIS; PIMAVANSERIN; MODEL; ANTAGONIST; DECREASES; SYMPTOMS; LIGANDS; PLACEBO;
D O I
10.1016/j.neulet.2019.134524
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Previous work has shown that chronic nicotine administration causes adaptive changes in 5-HT2A receptor expression. Based on this relationship, it was hypothesized that inactivating 5-HT2A receptors with the inverse agonists pimavanserin and volinanserin (MDL100907), would reduce the symptoms of nicotine withdrawal syndrome. Sprague-Dawley rats were rendered nicotine-dependent by subcutaneous infusion of nicotine bitartrate, 9 mg/kg/day for seven days. The infusions were then terminated, and 22 h later, rats were observed under "blind" conditions for somatically expressed behavioral nicotine withdrawal signs. One hour before observations, the nicotine dependent rats were injected i.p. with saline alone, or either 0.3 or 1.0 mg/kg pimavanserin in saline. Total withdrawal signs were reduced in a dose-dependent manner. A one-way ANOVA (total withdrawal signs as a function of dose) was highly significant, as was the descending linear trend of withdrawal signs as a function of dose. The 1.0 mg/kg dose reduced withdrawal signs nearly to the level exhibited by a comparison group of non-dependent rats injected with saline. A second experiment was conducted in a similar manner, which showed that volinanserin at 1.0 mg/kg but not 0.25 mg/kg also reduced nicotine withdrawal signs to nearly the level of non-dependent rats. In vitro experiments demonstrated that both pimavanserin and volinanserin potently antagonize 5-HT2A receptors, with approximately 25-fold, and 300-fold selectivity over 5-HT2C receptors, respectively. The results suggest that the 5-HT2A receptor contributes to mediating nicotine withdrawal syndrome, and thus represents a potential target for interventions to aid smoking cessation.
引用
收藏
页数:6
相关论文
共 50 条
[21]   Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists [J].
Moreno, Jose L. ;
Holloway, Terrell ;
Albizu, Laura ;
Sealfon, Stuart C. ;
Gonzalez-Maeso, Javier .
NEUROSCIENCE LETTERS, 2011, 493 (03) :76-79
[22]   Discovery of ß-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists [J].
Poulie, Christian B. M. ;
Pottie, Eline ;
Simon, Icaro A. ;
Harpsoe, Kasper ;
D'Andrea, Laura ;
Komarov, Igor V. ;
Gloriam, David E. ;
Jensen, Anders A. ;
Stove, Christophe P. ;
Kristensen, Jesper L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (18) :12031-12043
[23]   Imaging the 5-HT2C receptor with PET: Evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain [J].
Ridler, Khanum ;
Rizzo, Gaia ;
Burstein, Ethan S. ;
Forsberg Moren, Anton ;
Stepanov, Vladimir ;
Halldin, Christer ;
Rabiner, Eugenii A. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2025, 45 (02) :352-364
[24]   Effects of 5-HT2A and 5-HT2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats [J].
Creed-Carson, Meaghan ;
Oraha, Alhan ;
Nobrega, Jose N. .
BEHAVIOURAL BRAIN RESEARCH, 2011, 219 (02) :273-279
[25]   Engineering a region of bulk tolerance in the 5-HT2A receptor [J].
Westkaemper, RB ;
Hyde, EG ;
Choudhary, MS ;
Khan, N ;
Gelbar, EI ;
Glennon, RA ;
Roth, BL .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1999, 34 (05) :441-447
[26]   Changes in 5-HT2A Receptor Expression in Untreated, de novo Patients with Parkinson's Disease [J].
Melse, Maartje ;
Tan, Sonny K. H. ;
Temel, Yasin ;
van Kroonenburgh, Marinus J. P. G. ;
Leentjens, Albert F. G. .
JOURNAL OF PARKINSONS DISEASE, 2014, 4 (02) :283-287
[27]   Evaluation of structural effects on 5-HT2A receptor antagonism by aporphines: Identification of a new aporphine with 5-HT2A antagonist activity [J].
Ponnala, Shashikanth ;
Gonzales, Junior ;
Kapadia, Nirav ;
Navarro, Hernan A. ;
Harding, Wayne W. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (07) :1664-1667
[28]   Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders [J].
Abbas, Atheir ;
Roth, Bryan L. .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) :3251-3259
[29]   Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis [J].
Oguma, Takuya ;
Jino, Kohei ;
Nakahara, Kenji ;
Asada, Hidetsugu ;
Fuchino, Kouki ;
Nagatani, Kotaro ;
Kouki, Kensuke ;
Okamoto, Ryuji ;
Takai, Nozomi ;
Koda, Ken ;
Fujita, Sayaka ;
Sekiguchi, Yusuke ;
Yasuo, Kazuya ;
Mayumi, Kei ;
Abe, Ayane ;
Imono, Masaaki ;
Horiguchi, Naotaka ;
Iwata, So ;
Kusakabe, Ken-ichi .
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (16) :14478-14492
[30]   Synthesis and Evaluation of Dimeric Derivatives of 5-HT2A Receptor (5-HT2AR) Antagonist M-100907 [J].
Shashack, Matthew J. ;
Cunningham, Kathryn A. ;
Seitz, Patricia K. ;
McGinnis, Andrew ;
Smith, Thressa D. ;
Watson, Cheryl S. ;
Gilbertson, Scott R. .
ACS CHEMICAL NEUROSCIENCE, 2011, 2 (11) :640-644